24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publication dates

Heart Failure Industry, December 2014 Market Reports from Top Publishers

You might be interested in: Medical Equipment, Chronic Heart Failure, Therapeutics, more »


 
1-10 of 95 reports for Heart Failure

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • Dec 2014
  • by Firstword Pharma

... Indeed, the chronic heart failure agent is believed to represent both a significant growth driver for novartis as well as, alongside the pcsk9 class of dyslipidaemia products, among the first in a new wave of medicines ...

Ascenion GmbH - Product Pipeline Analysis, 2014 Update

Ascenion GmbH - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • December 2014
  • by Global Data

... Lncrna lipcar - heart failure 64lncrna lipcar - heart failure product overview 64metabolomics assay - ovarian endometriosis 65metabolomics assay - ovarian endometriosis product overview 65 ...

Cardio3 BioSciences SA (CARD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cardio3 BioSciences SA (CARD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2014
  • by Global Data

... heart failure, and acute myocardial infarction. The company has academic and industrial collaborations with mayo clinic, cardiovascular centre aalst, atmi and creganna contract design services. It also ...

GlaxoSmithKline S.A.E. (Symbol:BIOC) SWOT Analysis, Strategy, Revenues and Profits

GlaxoSmithKline S.A.E. (Symbol:BIOC) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Different companies. Glaxosmithkline's pharmaceutical product range includes treatments for asthma, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. It has a 99 ...

MetrioPharm AG (Symbol:MP5) SWOT Analysis, Strategy, Revenues and Profits

MetrioPharm AG (Symbol:MP5) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... C), chronic inflammatory diseases, wound healing, psoriasis and chronic heart failure. The companys product pipeline includes mp1000 and mp1032. Its mp1000 is small molecular immune modulators with anti ...

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... In the treatment of emphysema, chronic bronchitis, asthma with status asthmaticus, acute respiratory failure (arf), acute respiratory distress syndrome (ards), congestive heart failure with pulmonary edema ...

ARCA biopharma, Inc. (Symbol:ABIO) SWOT Analysis, Strategy, Revenues and Profits

ARCA biopharma, Inc. (Symbol:ABIO) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Tm, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure. The company offers products and services ...

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Develops medicines for the therapeutic areas, such as myocardial infarction, severe heart failure and other cardio-vascular disorders. Cardio is headquartered in kobe, hyogo, japan.This comprehensive ...

Critical Care Systems, Inc. SWOT Analysis, Strategy, Revenues and Profits

Critical Care Systems, Inc. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Critical care systems provides programs for anti-infectives, bleeding disorders, heart failure, immunoglobulins, nutrition support and specialty infusibles. The company offers comprehensive and cost ...

Cordex Pharma, Inc. (CDXP) - Strategic SWOT Analysis Review

Cordex Pharma, Inc. (CDXP) - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Of certain cardiac arrhythmias. Cdp-1050 is used during the condition of heart failure and vagonixen is used for the treatment of chronic obstructive pulmonary disease (copd). Atpotent is a sperm motility drug ...

About 2 300 reports for Heart Failure

Download Unlimited Documents from Trusted Public Sources

Hospital Industry in the US

  • September 2013
    89 pages
  • Hospital  

    Pneumonia  

    Heart Failure  

  • United States  

    North America  

View report >

2 Companies for Heart Failure

Read our Company Profiles

Bayer AG

Germany

Select Products Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.